Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

Stephen E. Kurtz; Christopher A. Eide; Andy Kaempf; Motomi Mori; Cristina E. Tognon; Uma Borate; Brian J. Druker; Jeffrey W. Tyner

doi:10.1038/s41375-018-0225-7

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

Stephen E. Kurtz, Christopher A. Eide, Andy Kaempf, Motomi Mori, Cristina E. Tognon, Uma Borate, Brian J. Druker, Jeffrey W. Tyner

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Original language	English (US)
Pages (from-to)	2025-2028
Number of pages	4
Journal	Leukemia
Volume	32
Issue number	9
DOIs	https://doi.org/10.1038/s41375-018-0225-7
State	Published - Sep 1 2018

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-018-0225-7

Cite this

@article{7dd10834f6b145098f32e0595a60d124,

title = "Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia",

author = "Kurtz, {Stephen E.} and Eide, {Christopher A.} and Andy Kaempf and Motomi Mori and Tognon, {Cristina E.} and Uma Borate and Druker, {Brian J.} and Tyner, {Jeffrey W.}",

note = "Funding Information: Acknowledgements Funding for this project was provided in part by a Leukemia Lymphoma Therapy Acceleration Grant to BJD and JWT, and by support provided by the Knight Cancer Research Institute (Oregon Health & Science University, OHSU). Also, this study was supported by grants from the National Cancer Institute (1U01CA217862, 1U54CA224019, 3P30CA069533-18S5). JWT received grants from the V Foundation for Cancer Research, the Gabrielle{\textquoteright}s Angel Foundation for Cancer Research, and the National Cancer Institute (1R01CA183947).",

year = "2018",

month = sep,

day = "1",

doi = "10.1038/s41375-018-0225-7",

language = "English (US)",

volume = "32",

pages = "2025--2028",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "9",

}

TY - JOUR

T1 - Dual inhibition of JAK1/2 kinases and BCL2

T2 - a promising therapeutic strategy for acute myeloid leukemia

AU - Kurtz, Stephen E.

AU - Eide, Christopher A.

AU - Kaempf, Andy

AU - Mori, Motomi

AU - Tognon, Cristina E.

AU - Borate, Uma

AU - Druker, Brian J.

AU - Tyner, Jeffrey W.

N1 - Funding Information: Acknowledgements Funding for this project was provided in part by a Leukemia Lymphoma Therapy Acceleration Grant to BJD and JWT, and by support provided by the Knight Cancer Research Institute (Oregon Health & Science University, OHSU). Also, this study was supported by grants from the National Cancer Institute (1U01CA217862, 1U54CA224019, 3P30CA069533-18S5). JWT received grants from the V Foundation for Cancer Research, the Gabrielle’s Angel Foundation for Cancer Research, and the National Cancer Institute (1R01CA183947).

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85052298210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052298210&partnerID=8YFLogxK

U2 - 10.1038/s41375-018-0225-7

DO - 10.1038/s41375-018-0225-7

M3 - Article

C2 - 30082821

AN - SCOPUS:85052298210

SN - 0887-6924

VL - 32

SP - 2025

EP - 2028

JO - Leukemia

JF - Leukemia

IS - 9

ER -

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this